{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,11,2]],"date-time":"2026-11-02T21:13:29Z","timestamp":1793654009921,"version":"4.5.1"},"reference-count":79,"publisher":"Springer Science and Business Media LLC","issue":"10","license":[{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T00:00:00Z","timestamp":1753142400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA286507"],"award-info":[{"award-number":["R01 CA286507"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R01 CA269733"],"award-info":[{"award-number":["R01 CA269733"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P50 CA217694"],"award-info":[{"award-number":["P50 CA217694"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["P30 CA008748"],"award-info":[{"award-number":["P30 CA008748"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["R00 HG012579"],"award-info":[{"award-number":["R00 HG012579"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"U.S. Department of Health & Human Services | National Institutes of Health","doi-asserted-by":"publisher","award":["U01 AT012984"],"award-info":[{"award-number":["U01 AT012984"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001021","name":"Damon Runyon Cancer Research Foundation","doi-asserted-by":"publisher","award":["CI-96-18"],"award-info":[{"award-number":["CI-96-18"]}],"id":[{"id":"10.13039\/100001021","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100002224","name":"Melanoma Research Foundation","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100002224","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Nat Cancer"],"DOI":"10.1038\/s43018-025-01009-x","type":"journal-article","created":{"date-parts":[[2025,7,22]],"date-time":"2025-07-22T09:03:57Z","timestamp":1753175037000},"page":"1638-1655","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":42,"title":["CAR-engineered lymphocyte persistence is governed by a FAS ligand\u2013FAS autoregulatory circuit"],"prefix":"10.1038","volume":"6","author":[{"ORCID":"https:\/\/orcid.org\/0009-0005-9031-2116","authenticated-orcid":false,"given":"Fei","family":"Yi","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tal","family":"Cohen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Natalie","family":"Zimmerman","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2301-112X","authenticated-orcid":false,"given":"Friederike","family":"D\u00fcndar","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul","family":"Zumbo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Razan","family":"Eltilib","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Erica J.","family":"Brophy","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hannah","family":"Arkin","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Judith","family":"Feucht","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michael V.","family":"Gormally","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christopher S.","family":"Hackett","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Korbinian N.","family":"Kropp","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-2713-0836","authenticated-orcid":false,"given":"Inaki","family":"Etxeberria","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Smita S.","family":"Chandran","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Zeguo","family":"Zhao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Winson","family":"Cai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anthony F.","family":"Daniyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-2903-5130","authenticated-orcid":false,"given":"Jae H.","family":"Park","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4179-4807","authenticated-orcid":false,"given":"Caleb A.","family":"Lareau","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katharine C.","family":"Hsu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-9031-8025","authenticated-orcid":false,"given":"Michel","family":"Sadelain","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-8006-7752","authenticated-orcid":false,"given":"Doron","family":"Betel","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9645-3896","authenticated-orcid":false,"given":"Christopher A.","family":"Klebanoff","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,7,22]]},"reference":[{"key":"1009_CR1","doi-asserted-by":"crossref","first-page":"359","DOI":"10.1038\/s41571-023-00754-1","volume":"20","author":"KM Cappell","year":"2023","unstructured":"Cappell, K. M. & Kochenderfer, J. N. Long-term outcomes following CAR T cell therapy: what we know so far. Nat. Rev. Clin. Oncol. 20, 359\u2013371 (2023).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1009_CR2","doi-asserted-by":"crossref","first-page":"64","DOI":"10.1056\/NEJMra1706169","volume":"379","author":"CH June","year":"2018","unstructured":"June, C. H. & Sadelain, M. Chimeric antigen receptor therapy. N. Engl. J. Med. 379, 64\u201373 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR3","doi-asserted-by":"crossref","first-page":"2561","DOI":"10.1056\/NEJMoa1610497","volume":"375","author":"CE Brown","year":"2016","unstructured":"Brown, C. E. et al. Regression of glioblastoma after chimeric antigen receptor T-cell therapy. N. Engl. J. Med. 375, 2561\u20132569 (2016).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR4","volume":"11","author":"M Hegde","year":"2020","unstructured":"Hegde, M. et al. Tumor response and endogenous immune reactivity after administration of HER2 CAR T cells in a child with metastatic rhabdomyosarcoma. Nat. Commun. 11, 3549 (2020).","journal-title":"Nat. Commun."},{"key":"1009_CR5","doi-asserted-by":"crossref","first-page":"1189","DOI":"10.1038\/s41591-022-01800-8","volume":"28","author":"C Qi","year":"2022","unstructured":"Qi, C. et al. Claudin18.2-specific CAR T cells in gastrointestinal cancers: phase 1 trial interim results. Nat. Med. 28, 1189\u20131198 (2022).","journal-title":"Nat. Med."},{"key":"1009_CR6","doi-asserted-by":"crossref","first-page":"934","DOI":"10.1038\/s41586-022-04489-4","volume":"603","author":"RG Majzner","year":"2022","unstructured":"Majzner, R. G. et al. GD2-CAR T cell therapy for H3K27M-mutated diffuse midline gliomas. Nature 603, 934\u2013941 (2022).","journal-title":"Nature"},{"key":"1009_CR7","doi-asserted-by":"crossref","first-page":"2844","DOI":"10.1038\/s41591-023-02612-0","volume":"29","author":"A Mackensen","year":"2023","unstructured":"Mackensen, A. et al. CLDN6-specific CAR-T cells plus amplifying RNA vaccine in relapsed or refractory solid tumors: the phase 1 BNT211-01 trial. Nat. Med. 29, 2844\u20132853 (2023).","journal-title":"Nat. Med."},{"key":"1009_CR8","doi-asserted-by":"crossref","first-page":"1379","DOI":"10.1038\/s41591-023-02363-y","volume":"29","author":"A Heczey","year":"2023","unstructured":"Heczey, A. et al. Anti-GD2 CAR-NKT cells in relapsed or refractory neuroblastoma: updated phase 1 trial interim results. Nat. Med. 29, 1379\u20131388 (2023).","journal-title":"Nat. Med."},{"key":"1009_CR9","doi-asserted-by":"crossref","first-page":"1284","DOI":"10.1056\/NEJMoa2210859","volume":"388","author":"F Del Bufalo","year":"2023","unstructured":"Del Bufalo, F. et al. GD2-CART01 for relapsed or refractory high-risk neuroblastoma. N. Engl. J. Med. 388, 1284\u20131295 (2023).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR10","doi-asserted-by":"crossref","first-page":"976","DOI":"10.1038\/s41573-023-00807-1","volume":"22","author":"M Ruella","year":"2023","unstructured":"Ruella, M., Korell, F., Porazzi, P. & Maus, M. V. Mechanisms of resistance to chimeric antigen receptor-T cells in haematological malignancies. Nat. Rev. Drug Discov. 22, 976\u2013995 (2023).","journal-title":"Nat. Rev. Drug Discov."},{"key":"1009_CR11","doi-asserted-by":"crossref","first-page":"449","DOI":"10.1056\/NEJMoa1709919","volume":"378","author":"JH Park","year":"2018","unstructured":"Park, J. H. et al. Long-term follow-up of CD19 CAR therapy in acute lymphoblastic leukemia. N. Engl. J. Med. 378, 449\u2013459 (2018).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR12","doi-asserted-by":"publisher","unstructured":"Kochenderfer, J. N. et al. Lymphoma remissions caused by anti-CD19 chimeric antigen receptor T cells are associated with high serum interleukin-15 Levels. J. Clin. Oncol. https:\/\/doi.org\/10.1200\/jco.2016.71.3024 (2017).","DOI":"10.1200\/jco.2016.71.3024"},{"key":"1009_CR13","doi-asserted-by":"crossref","first-page":"563","DOI":"10.1038\/s41591-018-0010-1","volume":"24","author":"JA Fraietta","year":"2018","unstructured":"Fraietta, J. A. et al. Determinants of response and resistance to CD19 chimeric antigen receptor (CAR) T cell therapy of chronic lymphocytic leukemia. Nat. Med. 24, 563\u2013571 (2018).","journal-title":"Nat. Med."},{"key":"1009_CR14","doi-asserted-by":"crossref","first-page":"1331","DOI":"10.1056\/NEJMoa1914347","volume":"382","author":"M Wang","year":"2020","unstructured":"Wang, M. et al. KTE-X19 CAR T-cell therapy in relapsed or refractory mantle-cell lymphoma. N. Engl. J. Med. 382, 1331\u20131342 (2020).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR15","doi-asserted-by":"crossref","first-page":"705","DOI":"10.1056\/NEJMoa2024850","volume":"384","author":"NC Munshi","year":"2021","unstructured":"Munshi, N. C. et al. Idecabtagene vicleucel in relapsed and refractory multiple myeloma. N. Engl. J. Med. 384, 705\u2013716 (2021).","journal-title":"N. Engl. J. Med."},{"key":"1009_CR16","doi-asserted-by":"publisher","unstructured":"Marin, D. et al. Safety, efficacy and determinants of response of allogeneic CD19-specific CAR-NK cells in CD19(+) B cell tumors: a phase 1\/2 trial. Nat. Med. https:\/\/doi.org\/10.1038\/s41591-023-02785-8 (2024).","DOI":"10.1038\/s41591-023-02785-8"},{"key":"1009_CR17","doi-asserted-by":"crossref","first-page":"85","DOI":"10.1038\/s41571-020-0426-7","volume":"18","author":"JA Myers","year":"2021","unstructured":"Myers, J. A. & Miller, J. S. Exploring the NK cell platform for cancer immunotherapy. Nat. Rev. Clin. Oncol. 18, 85\u2013100 (2021).","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"1009_CR18","doi-asserted-by":"crossref","first-page":"eabn5647","DOI":"10.1126\/science.abn5647","volume":"378","author":"KA Freitas","year":"2022","unstructured":"Freitas, K. A. et al. Enhanced T cell effector activity by targeting the Mediator kinase module. Science 378, eabn5647 (2022).","journal-title":"Science"},{"key":"1009_CR19","doi-asserted-by":"publisher","unstructured":"Menegatti, S. et al. Ablation of FAS confers allogeneic CD3(-) CAR T cells with resistance to rejection by T cells and natural killer cells. Nat. Biomed. Eng. https:\/\/doi.org\/10.1038\/s41551-024-01282-8 (2024).","DOI":"10.1038\/s41551-024-01282-8"},{"key":"1009_CR20","doi-asserted-by":"crossref","first-page":"728","DOI":"10.1016\/j.cell.2020.03.039","volume":"181","author":"TL Roth","year":"2020","unstructured":"Roth, T. L. et al. Pooled knockin targeting for genome engineering of cellular immunotherapies. Cell 181, 728\u2013744 e721 (2020).","journal-title":"Cell"},{"key":"1009_CR21","doi-asserted-by":"crossref","first-page":"4216","DOI":"10.1016\/j.cell.2023.08.013","volume":"186","author":"F Blaeschke","year":"2023","unstructured":"Blaeschke, F. et al. Modular pooled discovery of synthetic knockin sequences to program durable cell therapies. Cell 186, 4216\u20134234 e4233 (2023).","journal-title":"Cell"},{"key":"1009_CR22","doi-asserted-by":"publisher","unstructured":"Tieu, V. et al. A versatile CRISPR-Cas13d platform for multiplexed transcriptomic regulation and metabolic engineering in primary human T cells. Cell https:\/\/doi.org\/10.1016\/j.cell.2024.01.035 (2024).","DOI":"10.1016\/j.cell.2024.01.035"},{"key":"1009_CR23","doi-asserted-by":"crossref","first-page":"642","DOI":"10.1016\/j.molmed.2018.05.004","volume":"24","author":"F Yi","year":"2018","unstructured":"Yi, F., Frazzette, N., Cruz, A. C., Klebanoff, C. A. & Siegel, R. M. Beyond cell death: new functions for TNF family cytokines in autoimmunity and tumor immunotherapy. Trends Mol. Med. 24, 642\u2013653 (2018).","journal-title":"Trends Mol. Med."},{"key":"1009_CR24","doi-asserted-by":"crossref","first-page":"1551","DOI":"10.1172\/JCI121491","volume":"129","author":"TN Yamamoto","year":"2019","unstructured":"Yamamoto, T. N. et al. T cells genetically engineered to overcome death signaling enhance adoptive cancer immunotherapy. J. Clin. Invest. 129, 1551\u20131565 (2019).","journal-title":"J. Clin. Invest."},{"key":"1009_CR25","doi-asserted-by":"crossref","first-page":"e20191166","DOI":"10.1084\/jem.20191166","volume":"217","author":"SK Oda","year":"2020","unstructured":"Oda, S. K. et al. A Fas-4-1BB fusion protein converts a death to a pro-survival signal and enhances T cell therapy. J. Exp. Med. 217, e20191166 (2020).","journal-title":"J. Exp. Med."},{"key":"1009_CR26","doi-asserted-by":"crossref","first-page":"603","DOI":"10.1016\/j.omtn.2023.04.017","volume":"32","author":"C McKenzie","year":"2023","unstructured":"McKenzie, C. et al. Novel Fas-TNFR chimeras that prevent Fas ligand-mediated kill and signal synergistically to enhance CAR T cell efficacy. Mol. Ther. Nucleic Acids 32, 603\u2013621 (2023).","journal-title":"Mol. Ther. Nucleic Acids"},{"key":"1009_CR27","doi-asserted-by":"crossref","first-page":"4677","DOI":"10.1182\/blood-2004-08-3337","volume":"105","author":"G Dotti","year":"2005","unstructured":"Dotti, G. et al. Human cytotoxic T lymphocytes with reduced sensitivity to Fas-induced apoptosis. Blood 105, 4677\u20134684 (2005).","journal-title":"Blood"},{"key":"1009_CR28","doi-asserted-by":"crossref","first-page":"1592","DOI":"10.1038\/s41551-024-01287-3","volume":"8","author":"SE James","year":"2024","unstructured":"James, S. E. et al. Leucine zipper-based immunomagnetic purification of CAR T cells displaying multiple receptors. Nat. Biomed. Eng. 8, 1592\u20131614 (2024).","journal-title":"Nat. Biomed. Eng."},{"key":"1009_CR29","doi-asserted-by":"crossref","first-page":"1848","DOI":"10.1038\/s41591-022-01959-0","volume":"28","author":"NJ Haradhvala","year":"2022","unstructured":"Haradhvala, N. J. et al. Distinct cellular dynamics associated with response to CAR-T therapy for refractory B cell lymphoma. Nat. Med. 28, 1848\u20131859 (2022).","journal-title":"Nat. Med."},{"key":"1009_CR30","doi-asserted-by":"crossref","first-page":"1255","DOI":"10.1182\/blood-2011-02-337360","volume":"118","author":"X Wang","year":"2011","unstructured":"Wang, X. et al. A transgene-encoded cell surface polypeptide for selection, in vivo tracking, and ablation of engineered cells. Blood 118, 1255\u20131263 (2011).","journal-title":"Blood"},{"key":"1009_CR31","doi-asserted-by":"crossref","first-page":"1115","DOI":"10.1038\/sj.gt.3300506","volume":"4","author":"HF Gallardo","year":"1997","unstructured":"Gallardo, H. F., Tan, C. & Sadelain, M. The internal ribosomal entry site of the encephalomyocarditis virus enables reliable coexpression of two transgenes in human primary T lymphocytes. Gene Ther. 4, 1115\u20131119 (1997).","journal-title":"Gene Ther."},{"key":"1009_CR32","doi-asserted-by":"crossref","first-page":"2354","DOI":"10.1126\/science.288.5475.2354","volume":"288","author":"RM Siegel","year":"2000","unstructured":"Siegel, R. M. et al. Fas preassociation required for apoptosis signaling and dominant inhibition by pathogenic mutations. Science 288, 2354\u20132357 (2000).","journal-title":"Science"},{"key":"1009_CR33","doi-asserted-by":"crossref","first-page":"589","DOI":"10.1038\/nbt957","volume":"22","author":"AL Szymczak","year":"2004","unstructured":"Szymczak, A. L. et al. Correction of multi-gene deficiency in vivo using a single \u2018self-cleaving\u2019 2A peptide-based retroviral vector. Nat. Biotechnol. 22, 589\u2013594 (2004).","journal-title":"Nat. Biotechnol."},{"key":"1009_CR34","doi-asserted-by":"crossref","first-page":"4567","DOI":"10.1016\/j.cell.2023.08.041","volume":"186","author":"CA Tsuchida","year":"2023","unstructured":"Tsuchida, C. A. et al. Mitigation of chromosome loss in clinical CRISPR-Cas9-engineered T cells. Cell 186, 4567\u20134582 e4520 (2023).","journal-title":"Cell"},{"key":"1009_CR35","doi-asserted-by":"crossref","first-page":"1777","DOI":"10.1084\/jem.182.6.1777","volume":"182","author":"N Kayagaki","year":"1995","unstructured":"Kayagaki, N. et al. Metalloproteinase-mediated release of human Fas ligand. J. Exp. Med. 182, 1777\u20131783 (1995).","journal-title":"J. Exp. Med."},{"key":"1009_CR36","doi-asserted-by":"crossref","first-page":"5426","DOI":"10.1158\/1078-0432.CCR-07-0674","volume":"13","author":"RJ Brentjens","year":"2007","unstructured":"Brentjens, R. J. et al. Genetically targeted T cells eradicate systemic acute lymphoblastic leukemia xenografts. Clin. Cancer Res. 13, 5426\u20135435 (2007).","journal-title":"Clin. Cancer Res."},{"key":"1009_CR37","doi-asserted-by":"crossref","first-page":"318","DOI":"10.1172\/JCI81217","volume":"126","author":"CA Klebanoff","year":"2016","unstructured":"Klebanoff, C. A. et al. Memory T cell-driven differentiation of naive cells impairs adoptive immunotherapy. J. Clin. Invest. 126, 318\u2013334 (2016).","journal-title":"J. Clin. Invest."},{"key":"1009_CR38","doi-asserted-by":"crossref","first-page":"503","DOI":"10.1038\/s41586-019-1186-3","volume":"569","author":"M Ghandi","year":"2019","unstructured":"Ghandi, M. et al. Next-generation characterization of the Cancer Cell Line Encyclopedia. Nature 569, 503\u2013508 (2019).","journal-title":"Nature"},{"key":"1009_CR39","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/j.cell.2019.12.023","volume":"180","author":"DP Nusinow","year":"2020","unstructured":"Nusinow, D. P. et al. Quantitative proteomics of the Cancer Cell Line Encyclopedia. Cell 180, 387\u2013402 e316 (2020).","journal-title":"Cell"},{"key":"1009_CR40","volume":"7","author":"AC Cruz","year":"2016","unstructured":"Cruz, A. C. et al. Fas\/CD95 prevents autoimmunity independently of lipid raft localization and efficient apoptosis induction. Nat. Commun. 7, 13895 (2016).","journal-title":"Nat. Commun."},{"key":"1009_CR41","doi-asserted-by":"crossref","first-page":"552","DOI":"10.1158\/2159-8290.CD-19-0813","volume":"10","author":"N Singh","year":"2020","unstructured":"Singh, N. et al. Impaired death receptor signaling in leukemia causes antigen-independent resistance by inducing CAR T-cell dysfunction. Cancer Discov. 10, 552\u2013567 (2020).","journal-title":"Cancer Discov"},{"key":"1009_CR42","doi-asserted-by":"crossref","first-page":"597","DOI":"10.1182\/blood.2019002121","volume":"135","author":"O Dufva","year":"2020","unstructured":"Dufva, O. et al. Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity. Blood 135, 597\u2013609 (2020).","journal-title":"Blood"},{"key":"1009_CR43","doi-asserted-by":"crossref","first-page":"2113","DOI":"10.1084\/jem.20181454","volume":"216","author":"I Prager","year":"2019","unstructured":"Prager, I. et al. NK cells switch from granzyme B to death receptor-mediated cytotoxicity during serial killing. J. Exp. Med. 216, 2113\u20132127 (2019).","journal-title":"J. Exp. Med."},{"key":"1009_CR44","doi-asserted-by":"crossref","first-page":"946","DOI":"10.1038\/s41591-022-01786-3","volume":"28","author":"SS Chandran","year":"2022","unstructured":"Chandran, S. S. et al. Immunogenicity and therapeutic targeting of a public neoantigen derived from mutated PIK3CA. Nat. Med. 28, 946\u2013957 (2022).","journal-title":"Nat. Med."},{"key":"1009_CR45","doi-asserted-by":"crossref","first-page":"73","DOI":"10.1111\/j.1600-065X.2006.00457.x","volume":"214","author":"YT Bryceson","year":"2006","unstructured":"Bryceson, Y. T., March, M. E., Ljunggren, H. G. & Long, E. O. Activation, coactivation, and costimulation of resting human natural killer cells. Immunol. Rev. 214, 73\u201391 (2006).","journal-title":"Immunol. Rev."},{"key":"1009_CR46","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1038\/s41591-018-0290-5","volume":"25","author":"J Feucht","year":"2019","unstructured":"Feucht, J. et al. Calibration of CAR activation potential directs alternative T cell fates and therapeutic potency. Nat. Med. 25, 82\u201388 (2019).","journal-title":"Nat. Med."},{"key":"1009_CR47","doi-asserted-by":"crossref","first-page":"267","DOI":"10.1038\/6477","volume":"5","author":"J O\u2019Connell","year":"1999","unstructured":"O\u2019Connell, J., Bennett, M. W., O\u2019Sullivan, G. C., Collins, J. K. & Shanahan, F. Fas counter-attack\u2013the best form of tumor defense? Nat. Med. 5, 267\u2013268 (1999).","journal-title":"Nat. Med."},{"key":"1009_CR48","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1038\/cdd.2015.3","volume":"22","author":"ME Peter","year":"2015","unstructured":"Peter, M. E. et al. The role of CD95 and CD95 ligand in cancer. Cell Death Differ. 22, 549\u2013559 (2015).","journal-title":"Cell Death Differ."},{"key":"1009_CR49","doi-asserted-by":"crossref","first-page":"368","DOI":"10.1158\/2326-6066.CIR-14-0200","volume":"3","author":"A Kunkele","year":"2015","unstructured":"Kunkele, A. et al. Functional tuning of CARs reveals signaling threshold above which CD8+ CTL antitumor potency is attenuated due to cell Fas-FasL-dependent AICD. Cancer Immunol. Res. 3, 368\u2013379 (2015).","journal-title":"Cancer Immunol. Res."},{"key":"1009_CR50","doi-asserted-by":"crossref","first-page":"1245","DOI":"10.1038\/sj.leu.2400746","volume":"11","author":"L Karawajew","year":"1997","unstructured":"Karawajew, L. et al. Differential CD95 expression and function in T and B lineage acute lymphoblastic leukemia cells. Leukemia 11, 1245\u20131252 (1997).","journal-title":"Leukemia"},{"key":"1009_CR51","doi-asserted-by":"crossref","first-page":"2875","DOI":"10.1182\/blood.V91.8.2875.2875_2875_2885","volume":"91","author":"J Plumas","year":"1998","unstructured":"Plumas, J. et al. Tumor B cells from non-Hodgkin\u2019s lymphoma are resistant to CD95 (Fas\/Apo-1)-mediated apoptosis. Blood 91, 2875\u20132885 (1998).","journal-title":"Blood"},{"key":"1009_CR52","doi-asserted-by":"crossref","DOI":"10.1038\/s41419-024-06461-8","volume":"15","author":"MJ Montalvo","year":"2024","unstructured":"Montalvo, M. J. et al. Decoding the mechanisms of chimeric antigen receptor (CAR) T cell-mediated killing of tumors: insights from granzyme and Fas inhibition. Cell Death Dis. 15, 109 (2024).","journal-title":"Cell Death Dis."},{"key":"1009_CR53","doi-asserted-by":"crossref","first-page":"679","DOI":"10.1038\/s41591-018-0016-8","volume":"24","author":"B Chapuy","year":"2018","unstructured":"Chapuy, B. et al. Molecular subtypes of diffuse large B cell lymphoma are associated with distinct pathogenic mechanisms and outcomes. Nat. Med. 24, 679\u2013690 (2018).","journal-title":"Nat. Med."},{"key":"1009_CR54","doi-asserted-by":"crossref","first-page":"4266","DOI":"10.1182\/blood.V90.11.4266","volume":"90","author":"TH Landowski","year":"1997","unstructured":"Landowski, T. H., Qu, N., Buyuksal, I., Painter, J. S. & Dalton, W. S. Mutations in the Fas antigen in patients with multiple myeloma. Blood 90, 4266\u20134270 (1997).","journal-title":"Blood"},{"key":"1009_CR55","doi-asserted-by":"crossref","first-page":"491","DOI":"10.1182\/blood.2021015008","volume":"140","author":"MD Jain","year":"2022","unstructured":"Jain, M. D. et al. Whole-genome sequencing reveals complex genomic features underlying anti-CD19 CAR T-cell treatment failures in lymphoma. Blood 140, 491\u2013503 (2022).","journal-title":"Blood"},{"key":"1009_CR56","doi-asserted-by":"crossref","first-page":"210","DOI":"10.1016\/j.ccell.2022.12.005","volume":"41","author":"BJ Sworder","year":"2023","unstructured":"Sworder, B. J. et al. Determinants of resistance to engineered T cell therapies targeting CD19 in large B cell lymphomas. Cancer Cell 41, 210\u2013225 e215 (2023).","journal-title":"Cancer Cell"},{"key":"1009_CR57","doi-asserted-by":"crossref","first-page":"1274","DOI":"10.1158\/2326-6066.CIR-18-0065","volume":"6","author":"LK Hong","year":"2018","unstructured":"Hong, L. K. et al. CD30-redirected chimeric antigen receptor T cells target CD30(+) and CD30(-) embryonal carcinoma via antigen-dependent and Fas\/FasL interactions. Cancer Immunol. Res. 6, 1274\u20131287 (2018).","journal-title":"Cancer Immunol. Res."},{"key":"1009_CR58","doi-asserted-by":"crossref","first-page":"599","DOI":"10.1158\/2159-8290.CD-20-0756","volume":"11","author":"R Upadhyay","year":"2021","unstructured":"Upadhyay, R. et al. A critical role for Fas-mediated off-target tumor killing in T-cell immunotherapy. Cancer Discov. 11, 599\u2013613 (2021).","journal-title":"Cancer Discov"},{"key":"1009_CR59","doi-asserted-by":"crossref","first-page":"7126","DOI":"10.1158\/1078-0432.CCR-19-0421","volume":"25","author":"X Xu","year":"2019","unstructured":"Xu, X. et al. NKT cells coexpressing a GD2-specific chimeric antigen receptor and IL15 show enhanced in vivo persistence and antitumor activity against neuroblastoma. Clin. Cancer Res. 25, 7126\u20137138 (2019).","journal-title":"Clin. Cancer Res."},{"key":"1009_CR60","doi-asserted-by":"crossref","first-page":"5708","DOI":"10.1158\/1078-0432.CCR-13-3451","volume":"20","author":"DC Deniger","year":"2014","unstructured":"Deniger, D. C. et al. Activating and propagating polyclonal \u03b3\u03b4 T cells with broad specificity for malignancies. Clin. Cancer Res. 20, 5708\u20135719 (2014).","journal-title":"Clin. Cancer Res."},{"key":"1009_CR61","doi-asserted-by":"crossref","first-page":"123","DOI":"10.1038\/sj.neo.7900018","volume":"1","author":"MC Gong","year":"1999","unstructured":"Gong, M. C. et al. Cancer patient T cells genetically targeted to prostate-specific membrane antigen specifically lyse prostate cancer cells and release cytokines in response to prostate-specific membrane antigen. Neoplasia 1, 123\u2013127 (1999).","journal-title":"Neoplasia"},{"key":"1009_CR62","first-page":"2871","volume":"71","author":"JC Lee","year":"2011","unstructured":"Lee, J. C. et al. In vivo inhibition of human CD19-targeted effector T cells by natural T regulatory cells in a xenotransplant murine model of B cell malignancy. Cancer Res. 71, 2871\u20132881 (2011).","journal-title":"Cancer Res."},{"key":"1009_CR63","doi-asserted-by":"crossref","first-page":"689","DOI":"10.1097\/CJI.0b013e3181ac6138","volume":"32","author":"JN Kochenderfer","year":"2009","unstructured":"Kochenderfer, J. N. et al. Construction and preclinical evaluation of an anti-CD19 chimeric antigen receptor. J. Immunother. 32, 689\u2013702 (2009).","journal-title":"J. Immunother."},{"key":"1009_CR64","doi-asserted-by":"crossref","first-page":"e30264","DOI":"10.1371\/journal.pone.0030264","volume":"7","author":"CJ Denman","year":"2012","unstructured":"Denman, C. J. et al. Membrane-bound IL-21 promotes sustained ex vivo proliferation of human natural killer cells. PLoS ONE 7, e30264 (2012).","journal-title":"PLoS ONE"},{"key":"1009_CR65","doi-asserted-by":"crossref","first-page":"1361","DOI":"10.1158\/2326-6066.CIR-24-0246","volume":"12","author":"W Cai","year":"2024","unstructured":"Cai, W. et al. Augmenting CAR T-cell Functions with LIGHT. Cancer Immunol. Res. 12, 1361\u20131379 (2024).","journal-title":"Cancer Immunol. Res."},{"key":"1009_CR66","doi-asserted-by":"publisher","unstructured":"Notti, R. Q. et al. The resting and ligand-bound states of the membrane-embedded human T-cell receptor-CD3 complex. Preprint at bioRxiv https:\/\/doi.org\/10.1101\/2023.08.22.554360 (2024).","DOI":"10.1101\/2023.08.22.554360"},{"key":"1009_CR67","first-page":"3629","volume":"57","author":"H Liu","year":"1997","unstructured":"Liu, H. et al. Monoclonal antibodies to the extracellular domain of prostate-specific membrane antigen also react with tumor vascular endothelium. Cancer Res. 57, 3629\u20133634 (1997).","journal-title":"Cancer Res."},{"key":"1009_CR68","doi-asserted-by":"crossref","first-page":"6733","DOI":"10.1073\/pnas.92.15.6733","volume":"92","author":"I Riviere","year":"1995","unstructured":"Riviere, I., Brose, K. & Mulligan, R. C. Effects of retroviral vector design on expression of human adenosine deaminase in murine bone marrow transplant recipients engrafted with genetically modified cells. Proc. Natl Acad. Sci. USA 92, 6733\u20136737 (1995).","journal-title":"Proc. Natl Acad. Sci. USA"},{"key":"1009_CR69","volume":"21","author":"C Wang","year":"2020","unstructured":"Wang, C. et al. Integrative analyses of single-cell transcriptome and regulome using MAESTRO. Genome Biol. 21, 198 (2020).","journal-title":"Genome Biol."},{"key":"1009_CR70","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1038\/s41590-018-0276-y","volume":"20","author":"D Aran","year":"2019","unstructured":"Aran, D. et al. Reference-based analysis of lung single-cell sequencing reveals a transitional profibrotic macrophage. Nat. Immunol. 20, 163\u2013172 (2019).","journal-title":"Nat. Immunol."},{"key":"1009_CR71","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1038\/nbt.4091","volume":"36","author":"L Haghverdi","year":"2018","unstructured":"Haghverdi, L., Lun, A. T. L., Morgan, M. D. & Marioni, J. C. Batch effects in single-cell RNA-sequencing data are corrected by matching mutual nearest neighbors. Nat. Biotechnol. 36, 421\u2013427 (2018).","journal-title":"Nat. Biotechnol."},{"key":"1009_CR72","doi-asserted-by":"crossref","first-page":"1179","DOI":"10.1093\/bioinformatics\/btw777","volume":"33","author":"DJ McCarthy","year":"2017","unstructured":"McCarthy, D. J., Campbell, K. R., Lun, A. T. & Wills, Q. F. Scater: pre-processing, quality control, normalization and visualization of single-cell RNA-seq data in R. Bioinformatics 33, 1179\u20131186 (2017).","journal-title":"Bioinformatics"},{"key":"1009_CR73","first-page":"2122","volume":"5","author":"AT Lun","year":"2016","unstructured":"Lun, A. T., McCarthy, D. J. & Marioni, J. C. A step-by-step workflow for low-level analysis of single-cell RNA-seq data with Bioconductor. F1000Res 5, 2122 (2016).","journal-title":"F1000Res"},{"key":"1009_CR74","doi-asserted-by":"crossref","first-page":"5535","DOI":"10.1093\/bioinformatics\/btaa1011","volume":"36","author":"DG Bunis","year":"2021","unstructured":"Bunis, D. G., Andrews, J., Fragiadakis, G. K., Burt, T. D. & Sirota, M. dittoSeq: universal user-friendly single-cell and bulk RNA sequencing visualization toolkit. Bioinformatics 36, 5535\u20135536 (2021).","journal-title":"Bioinformatics"},{"key":"1009_CR75","volume":"15","author":"W Li","year":"2014","unstructured":"Li, W. et al. MAGeCK enables robust identification of essential genes from genome-scale CRISPR\/Cas9 knockout screens. Genome Biol. 15, 554 (2014).","journal-title":"Genome Biol"},{"key":"1009_CR76","doi-asserted-by":"crossref","first-page":"2133","DOI":"10.1038\/s41591-022-02003-x","volume":"28","author":"Y Li","year":"2022","unstructured":"Li, Y. et al. KIR-based inhibitory CARs overcome CAR-NK cell trogocytosis-mediated fratricide and tumor escape. Nat. Med. 28, 2133\u20132144 (2022).","journal-title":"Nat. Med."},{"key":"1009_CR77","doi-asserted-by":"crossref","first-page":"519","DOI":"10.1182\/blood-2015-11-683847","volume":"128","author":"M Sabatino","year":"2016","unstructured":"Sabatino, M. et al. Generation of clinical-grade CD19-specific CAR-modified CD8+ memory stem cells for the treatment of human B-cell malignancies. Blood 128, 519\u2013528 (2016).","journal-title":"Blood"},{"key":"1009_CR78","doi-asserted-by":"crossref","first-page":"401","DOI":"10.1158\/2159-8290.CD-12-0095","volume":"2","author":"E Cerami","year":"2012","unstructured":"Cerami, E. et al. The cBio cancer genomics portal: an open platform for exploring multidimensional cancer genomics data. Cancer Discov. 2, 401\u2013404 (2012).","journal-title":"Cancer Discov."},{"key":"1009_CR79","doi-asserted-by":"crossref","first-page":"D1420","DOI":"10.1093\/nar\/gkaa1020","volume":"49","author":"D Sun","year":"2021","unstructured":"Sun, D. et al. TISCH: a comprehensive web resource enabling interactive single-cell transcriptome visualization of tumor microenvironment. Nucleic Acids Res. 49, D1420\u2013D1430 (2021).","journal-title":"Nucleic Acids Res."}],"container-title":["Nature Cancer"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01009-x","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01009-x.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,10,30]],"date-time":"2025-10-30T18:09:45Z","timestamp":1761847785000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.nature.com\/articles\/s43018-025-01009-x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,7,22]]},"references-count":79,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2025,10]]}},"alternative-id":["1009"],"URL":"https:\/\/doi.org\/10.1038\/s43018-025-01009-x","relation":{},"ISSN":["2662-1347"],"issn-type":[{"value":"2662-1347","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,7,22]]},"assertion":[{"value":"23 February 2024","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"2 June 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"22 July 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"C.A.K. and F.Y. are inventors on patents (PCT\/US2021\/0214415, \u2018Immunoresponsive cells expressing dominant negative FAS and uses thereof\u2019 and PCT\/US2023\/005877, \u2018Novel dominant negative FAS polypeptides, cells comprising thereof and uses thereof\u2019) related to this work. J.F. and M.S. are inventors on a patent (PCT\/ US18\/68134, \u2018Enhanced chimeric antigen receptors and uses thereof\u2019) related to this work which has been licensed to Atara Biotherapeutics, Fate Therapeutics, Takeda Pharmaceuticals, Mnemo Therapeutics and Minerva Biotechnologies. C.A.K. is a scientific co-founder and holds equity in Affini-T Therapeutics. C.A.K. has previously consulted for, or is on the scientific and\/or clinical advisory boards of, Achilles Therapeutics, Affini-T Therapeutics, Aleta BioTherapeutics, Bellicum Pharmaceuticals, BMS, Catamaran Bio, Cell Design Labs, Decheng Capital, G1 Therapeutics, Klus Pharma, Obsidian Therapeutics, PACT Pharma, Roche\/Genentech, Royalty Pharma, Stereo Biotherapeutics and T-knife. S.S.C. is a scientific advisor and equity holder in Affini-T Therapeutics. A.F.D. is the chief scientific officer of Promicell Therapeutics and holds equity in the company. A.F.D. is listed as an inventor on multiple patents related to CAR-T cell therapy and may be eligible to receive a portion of royalties paid to MSK by Caribou Biosciences, Tigen Pharma SA, Promicell Therapeutics and other entities that have optioned or licensed these technologies from MSK. C.A.L. is a scientific co-founder and holds equity in Cartography Biosciences. J.H.P. received consulting fees from Adaptive Biotechnologies, Affyimmune Therapeutics, Amgen, Autolus, Ascentage, Be Biopharma, Beigene, Bright Pharmaceutical Services, Caribou Biosciences, Curocell, Galapagos, In8Bio, Iovance, Jazz Pharmaceuticals, Kite, Medpace, Pfizer, Servier, Sobi, Synthekine and Takeda; received honoraria from OncLive, Physician Education Resource and MJH Life Sciences; serves on scientific advisory board of Allogene Therapeutics, Artiva Biotherapeutics and Green Cross Biopharma; and received institutional research funding from Autolus, Genentech, Fate Therapeutics, InCyte, Servier and Takeda. M.S. reports grants from Atara Biotherapeutics, Fate Therapeutics, Mnemo Therapeutics and Takeda outside the submitted work. Additionally, M.S. has patents issued and licensed to Juno Therapeutics, Atara Biotherapeutics, Fate Therapeutics, Takeda Pharmaceuticals and Alaya Bio. The remaining authors declare no competing interests.","order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}]}}